10 recruiting. 10 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 10 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines Lesigercept, Placebo - Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Yuhan Corporation | 150 | 2026-03-26 | 2026-04-15 |
| Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria ICP-332 Tablets, ICP-332 placebo Tablets - Chronic Spontaneous Urticaria (CSU) | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 344 | 2026-02-13 | 2026-04-21 |
| Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) CM512 injection, placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 48 | 2025-11-27 | 2026-04-09 |
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Pfizer | 200 | 2025-10-30 | 2026-10-26 |
| Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) Berinert, Placebo for Berinert - Kidney Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2025-09-22 | 2026-02-27 |
| An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria Placebo, 0.5 mg epinephrine, 1 mg epinephrine - Urticaria Chronic | Phase 2 | Recruiting | ARS Pharmaceuticals, Inc. | 42 | 2025-07-09 | 2026-09-16 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Remibrutinib, Placebo - Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 44 | 2025-05-22 | 2026-09-28 |
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
| Trial of JYB1904 in Chronic Spontaneous Urticaria. JYB1904, Omalizumab - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Jemincare | 135 | 2024-08-04 | 2024-11-29 |
Chronic Urticaria (8) · Angioedemas, Hereditary (2) · Angioedema (1) · Chronic Inducible Urticaria (1) · Cold Urticaria (1) · Familial dermographism (1) · Pruritus (1) · Urticaria, Solar (1)
Hypersensitivity (10) · Hypersensitivity, Immediate (10) · Immune System Diseases (10) · Skin Diseases (10) · Skin Diseases, Vascular (10) · Skin and Connective Tissue Diseases (10) · Chronic Disease (8) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hereditary Complement Deficiency Diseases (2)
Complement C1 Inhibitor Protein (1) · Epinephrine (1) · Omalizumab (1) · PF-06651600 (1) · remibrutinib (1)
ARS Pharmaceuticals, Inc. (1) · Bambusa Therapeutics (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Institute for Asthma and Allergy (1) · Jemincare (1) · Keymed Biosciences Co.Ltd (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Yuhan Corporation (1)
China (6) · United States (5) · Germany (3) · Poland (3) · Bulgaria (2) · South Korea (2) · Spain (2) · Canada (1) · France (1) · Japan (1) · Taiwan (1)
Litao Zhang (1) · Peter S Heeger, MD (1) · Sindhu Chandran, MBBS, MD (1) · Stanley Jordan, MD (1) · Zuotao Zhao (1)
2025 (1)